(Bloomberg) -- Saudi Arabia’s sovereign wealth fund has picked banks for the planned initial public offering of the kingdom’s largest medical procurement firm, as it hunts for cash to finance the crown prince’s ambitious economic agenda. Most Read from Bloomberg Trump Shooting Changes Biden’s Plan to Revive 2024 Campaign Trump Emerges Defiant From Rally Attack Set to Shake Up ’24 Race BlackRock Says Gunman From Trump Rally Appeared in Firm’s Ad I Was at the Trump Rally Where He Was Shot. Here Is What I Saw Trump’s Bloodied, Defiant Image After Shooting Pumps Up His Base JPMorgan Chase & Co., Morgan Stanley and SNB Capital have been hired to work on Nupco’s IPO, according to people familiar with the matter. The deal could come as soon as this year, the people said, asking not to be identified as the information isn’t public. The share sale would likely raise less than $1 billion, Bloomberg News reported in May. Representatives for the Public Investment Fund, JPMorgan, Morgan Stanley and SNB Capital declined to comment. New from Bloomberg: Get the Mideast Money newsletter, a weekly look at the intersection of wealth and power in the region. Saudi Arabia is considering cutting spending on some of its biggest development projects as it grapples with the scale of Crown Prince Mohammed Bin Salman’s Vision 2030 agenda, Bloomberg News reported last week. That’ll put additional pressure on the PIF, which is the main entity tasked with driving the multi-trillion-dollar economic diversification plan. The $925 billion wealth fund has listed several of its portfolio companies in recent years and is becoming an active debt issuer. Saudi Arabia has been a busy market for share sales over the past few years, together with other Gulf countries, as governments sought to raise funds to reduce their reliance on the energy sector while encouraging private firms to list to develop their capital markets. Founded in 2009, Nupco seeks to raise the level of health services in the kingdom, improve the efficiency of government spending for the purchase of medical supplies and increase the effectiveness of supply chains in the public health-care sector, according to its website. Health care is one of the main focus areas of Vision 2030 as the country seeks to develop its drug industry. Dr Soliman Abdel Kader Fakeeh Hospital Co. raised $763 million in a Riyadh IPO in June, but its shares have risen just 2% from their offer price. Most Read from Bloomberg Businessweek How Rivian Became the Anti-Tesla Asia Is The New Hot Destination for Luxury Travel Ukraine Is Fighting Russia With Toy Drones and Duct-Taped Bombs French Elections Result Is Least Worst Outcome for Business Looser Visa Rules for Indian Travelers Stoke a Tourism Boom ©2024 Bloomberg L.P.
Saudi Wealth Fund Picks JPMorgan, Morgan Stanley for Nupco IPO
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...